Chemoimmunotherapy for Multiple Myeloma-VMCP + VCAP vs. VMCP-VBAP vs. MP for Remission Induction Therapy: VMCP vs. VMCP + Levamisole for Maintenance After Remission Induction

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience

J Crowley;J Jacobson;R Alexanian Seminars in Hematology 38(3):203-208

Alternating combination chemotherapy and Levamisole improves survival in multiple myeloma: A Southwest Oncology Group study.

SE Salmon;A Haut;JD Bonnet;M Amare;JK Weick;BGM Durie;DO Dixon J Clin Oncol 1:453-461

Addition of Levamisole to chemotherapy improves survival in multiple myeloma.

SE Salmon Am Soc Hematol

Chemoimmunotherapy for multiple myeloma: Effect of Levamisole during maintenance. Preliminary report of a Southwest Oncology Group study.

SE Salmon;R Alexanian;DO Dixon In: Immunotherapy of Human Cancer. WD Terry, SA Rosenberg, eds. New York: Elsevier-North Holland, 61-66

Chemoimmunotherapy for multiple myeloma: Effect of Levamisole.

SE Salmon;R Alexanian;DO Dixon Immunotherapy of Cancer: Present Status of Trials in Man, p. 28, April

Non-Cross resistant combination chemotherapy improves survival in multiple myeloma.

S Salmon;R Alexanian;D Dixon Blood 54:207a (#552)

Clinical staging and new therapeutic approaches in multiple myeloma.

SE Salmon;BGM Durie In: Recent Results in Cancer Research, Vol. 65, Mathe, G., Seligmann, M., and Tubiana, M. (eds), Springer-Verlag, Berlin/Heidelberg, pp. 12-20